Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00549770 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
A Phase 2 study of Hypertension, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,334
- Enrollment target
- 20
- Study locations
NCT00549770: Completed Phase 2 study of Hypertension, sponsored by Novartis Pharmaceuticals.
NCT00549770 is a Phase 2 study of Hypertension that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,334 participants, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00549770, a Phase 2 study of Hypertension, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,334 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study was a dose-ranging efficiacy study in patients with essential hypertension to assess the blood pressure lowering effect, and safety of LCZ696 compared to valsartan and placebo. The study will also evaluate the efficacy and safety of AHU377 as compared to placebo.
Primary Outcome
Sitting BP measurements were performed at screening through the end of the study at every study visit. A negative change from baseline indicates improvement.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Valsartan
- DRUG LCZ696
- DRUG AHU377
Study Locations (20)
California
- Novartis Investigative Site - Buena Park
- Novartis Investigative Site - Fair Oaks
- Novartis Investigative Site - Long Beach
- Novartis Investigative Site - Los Angeles
- Novartis Investigative Site - Orangevale
- Novartis Investigative Site - Santa Ana
- Novartis Investigative Site - Stockton
- Novartis Investigative Site - Tustin
Florida
- Novartis Investigative Site - Jacksonville
- Novartis Investigative Site - Pembroke Pines
- Novartis Investigative Site - Pembroke Pines
- Novartis Investigative Site - Pensacola
Illinois
- Novartis Investigative Site - Chicago
- Novartis Investigative Site - Chicago
- Novartis Investigative Site - Peoria
Alabama
- Novartis Investigative Site - Birmingham
- Novartis Investigative Site - Muscle Shoals
Arizona
- Novartis Investigative Site - Chandler
Georgia
- Novartis Investigative Site - Augusta
Louisiana
- Novartis Investigative Site - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,334 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
What the finished NCT00549770 record still lists
NCT00549770 is an interventional study that assigns participants to a tested intervention. Its 1,334 participants enrollment target places it among the larger protocols in the corpus, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00549770 names 20 study sites across 7 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00549770 about?
NCT00549770 is a clinical study titled "Efficacy and Safety of LCZ696A in Patients With Essential Hypertension". This study was a dose-ranging efficiacy study in patients with essential hypertension to assess the blood pressure lowering effect, and safety of LCZ696 compared to valsartan and placebo. The study will also evaluate the efficacy and safety of AHU377 as compared to placebo.
What is the current status of trial NCT00549770?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,334 participants. The study started on 2007-09. Estimated completion is 2008-07.
What conditions does trial NCT00549770 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00549770?
The interventions under investigation include: Placebo (DRUG), Valsartan (DRUG), LCZ696 (DRUG), AHU377 (DRUG).
Who is sponsoring clinical trial NCT00549770?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00549770 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00549770's enrollment target sits among peer trials
1,334 49th of 470 higher than 422 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
RECRUITING · Phase 2
-
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
RECRUITING · Phase 2
-
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
RECRUITING · Phase 2
-
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
RECRUITING · Phase 2
-
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
RECRUITING · Phase 2
-
Virtual Diabetes Group Visits Across Health Systems
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06972056 · 1,335 participants · Phase 4
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- NCT05415761 · 1,332 participants · NA
Comparative Effectiveness of Mobile Health Smoking Cessation Approaches Among Underserved Patients in Primary Care
- NCT05511298 · 1,332 participants
Empowering Students Project
- NCT06934876 · 1,332 participants
Waveform Capnography Compared to Colorimetric Carbon Dioxide Detection During Tracheal Intubation of Critically Ill Adults
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia